Breaks Categories: Stock Spotlights

ThursdayJul 01, 2021 12:36 pm

BioMedNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s founder and Chief Medical Officer Dr. G. Dave Singh shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product. “Dr. Singh’s primary goal with this book is to spread…

Continue Reading

ThursdayJul 01, 2021 12:20 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. Fluence, a psychedelic therapy educational platform, will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials, while Clinlogix, a global novel pharmaceutical product contract research organization, will provide support services. “Tryp announced on May 25 that global pharmaceutical contract development and…

Continue Reading

WednesdayJun 23, 2021 2:56 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Focused on Greater Supplement Effectiveness

Healthy Extracts (OTCQB: HYEX) develops, sells and distributes proprietary products with proven health benefits through its portfolio of wholly owned subsidiaries that currently comprises Ultimate Brain Nutrients(TM) (“UBN”) and BergametNA(TM). UBN creates formulations that improve brain health while BergametNA develops powerfully proven supplements sourced from the Citrus Bergamot Superfruit(TM) (“bergamot”) and which target cardiovascular and immune health. “Bergamot has a host of health benefits as it is a source of high concentrations of polyphenolic flavanones, measured in terms of the bergamot polyphenolic fraction (‘BPF’),” reads a recent article. Dr. Gerald Haase, MD, a clinical professor of surgery at the University…

Continue Reading

WednesdayJun 23, 2021 2:14 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Setting Stage for Strengthened Demand for Blue Light Cystoscopy

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA,” reads a recent article. “The additional testing and specification development focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can…

Continue Reading

TuesdayJun 22, 2021 1:39 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of Berubicin for adult glioblastoma multiforme (“GBM”) in the second quarter. Additionally, its sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients and is also…

Continue Reading

TuesdayJun 22, 2021 1:19 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for Parkinson’s Disease was completed in March 2021. Due to the favorable outcome of the study, the Rotigotine development program will be advanced to include a pivotal human trial.” The article, which documented XPhyto’s advancements so…

Continue Reading

MondayJun 21, 2021 1:43 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partnering to Improve Standard of Care, Provide Turnkey Solutions in Plant-Based Medicine

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with doctors as well as government and university research centers to reduce the variations in treatment plans and trials. The company, which has developed and uses dose-measuring internet-of-things (“IoT”) devices to collect HIPPA-compliant data to improve future medical treatments, is guided by the need to transform patient care. Key to this focus is utilizing big data and AI to reshape how the world understands plant-based medicine. A recent article reads, “RYAH partners with doctors to improve the standard of care for patients and researchers to…

Continue Reading

MondayJun 21, 2021 11:27 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Revolutionizing Portable EEG Diagnostics Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company, has created powerful yet affordable solutions that bring brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. Concussions resulting from head trauma in contact sports are usually minor; however, some can lead to significant long-term cognitive, physical and psychosocial impairments. “Unfortunately,” observes a recent article, “at this moment, it is challenging to differentiate between the two.” CT is the most commonly used imaging procedure but is not effective when conducting a post-concussion examination. MRIs and neuropsychologic testing are somewhat more effective but are…

Continue Reading

FridayJun 18, 2021 1:31 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Differentiating Itself as Premier Provider of Vital Products

United Medical Equipment (“UME,” “UMEBSNI”) stands out in an environment fraught with fraudsters who emerged due to the soaring demand for personal protective equipment (“PPE”). “As the virus spread, an immediate and drastic need for personal protective equipment exploded. This soaring demand for PPE was quickly accompanied by PPE-related fraud,” notes a recent article. PPE fraud involves selling counterfeit testing kits, surgical gowns, gloves, facial masks, and cleaning products, as well as making false or misleading efficacy claims. “As a trusted supplier of FDA-approved COVID-19 rapid antibody test kits and PPE equipment, UME stands out in this environment where buyers…

Continue Reading

ThursdayJun 17, 2021 2:47 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Innovative System Expected to Lead to More Successful Surgical Outcomes

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed and patented its i/Blue Imaging System(TM), which will directly address the problems associated with treating early stage bladder cancer using existing cystoscope technology. “Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light images. The switching process makes orientation and navigation within the bladder a challenge for surgeons,” explains a recent article. Imagin’s system will display real-time white and blue light images simultaneously, side-by-side, removing the challenge of constantly switching and reorienting. In addition, unlike current BLC technology,…

Continue Reading